Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the 'suboptimal therapy' patient population.
Chappell M, Sanderson A, Arun T, Green C, Davies H, Tempest M, Watkins D, Arber M, McCool R. Chappell M, et al. Among authors: arun t. J Neurol Sci. 2024 Sep 15;464:123172. doi: 10.1016/j.jns.2024.123172. Epub 2024 Aug 6. J Neurol Sci. 2024. PMID: 39142083 Free article. Review.
Real-world persistence of multiple sclerosis disease-modifying therapies.
Tallantyre EC, Dobson R, Froud JLJ, St John FA, Anderson VM, Arun T, Buckley L, Evangelou N, Ford HL, Galea I, George S, Gray OM, Hibbert AM, Hu M, Hughes SE, Ingram G, Kalra S, Lim CE, Mathews JTM, McDonnell GV, Mescall N, Norris S, Ramsay SJ, Rice CM, Russell MJ, Shawe-Taylor MJ, Williams TE, Harding KE, Robertson NP. Tallantyre EC, et al. Among authors: arun t. Eur J Neurol. 2024 Jul;31(7):e16289. doi: 10.1111/ene.16289. Epub 2024 Apr 3. Eur J Neurol. 2024. PMID: 38567516 Free PMC article.
Influence of physicians' risk perception on switching treatments between high- efficacy and non-high-efficacy disease‑modifying therapies in multiple sclerosis.
Seifer G, Arun T, Capela C, Laureys G, Jones E, Dominguez-Castro P, Sanchez-de la Rosa R, Hiltl S, Iaffaldano P. Seifer G, et al. Among authors: arun t. Mult Scler Relat Disord. 2023 Aug;76:104770. doi: 10.1016/j.msard.2023.104770. Epub 2023 May 26. Mult Scler Relat Disord. 2023. PMID: 37307690 Free article.
ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK.
Jacobs BM, Schalk L, Dunne A, Scalfari A, Nandoskar A, Gran B, Mein CA, Sellers C, Spilker C, Rog D, Visentin E, Bezzina EL, Uzochukwu E, Tallantyre E, Wozniak E, Sacre E, Hassan-Smith G, Ford HL, Harris J, Bradley J, Breedon J, Brooke J, Kreft KL, Tuite Dalton K, George K, Papachatzaki M, O'Malley M, Peter M, Mattoscio M, Rhule N, Evangelou N, Vinod N, Quinn O, Shamji R, Kaimal R, Boulton R, Tanveer R, Middleton R, Murray R, Bellfield R, Hoque S, Patel S, Raj S, Gumus S, Mitchell S, Sawcer S, Arun T, Pogreban T, Brown TL, Begum T, Antoine V, Rashid W, Noyce AJ, Silber E, Morris H, Giovannoni G, Dobson R. Jacobs BM, et al. Among authors: arun t. BMJ Open. 2023 May 17;13(5):e071656. doi: 10.1136/bmjopen-2023-071656. BMJ Open. 2023. PMID: 37197821 Free PMC article.
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trial.
Williams T, John N, Calvi A, Bianchi A, De Angelis F, Doshi A, Wright S, Shatila M, Yiannakas MC, Chowdhury F, Stutters J, Ricciardi A, Prados F, MacManus D, Braisher M, Blackstone J, Ciccarelli O, Gandini Wheeler-Kingshott CAM, Barkhof F, Chataway J; UCL MS-STAT2 investigators. Williams T, et al. Eur J Neurol. 2023 Sep;30(9):2769-2780. doi: 10.1111/ene.15924. Epub 2023 Jun 23. Eur J Neurol. 2023. PMID: 37318885 Clinical Trial.
Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance.
Rashid W, Ciccarelli O, Leary SM, Arun T, Doshi A, Evangelou N, Ford HL, Hobart J, Jacob S, Muraro PA, Murray K, Palace J, Dobson R; Association Of British Neurologists Multiple Sclerosis and Neuroinflammation Advisory Group. Rashid W, et al. Among authors: arun t. Pract Neurol. 2024 Nov 11:pn-2024-004228. doi: 10.1136/pn-2024-004228. Online ahead of print. Pract Neurol. 2024. PMID: 39532459 Review.
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK.
Blackstone J, Williams T, Nicholas JM, Bordea E, De Angelis F, Bianchi A, Calvi A, Doshi A, John N, Apap Mangion S, Wade C, Merry R, Barton G, Lyle D, Jarman E, Mahad D, Shehu A, Arun T, McDonnell G, Geraldes R, Craner M, Hillier C, Ganesalingam J, Fisniku L, Hobart J, Spilker C, Robertson N, Kalra S, Pluchino S, Harikrishnan S, Mattoscio M, Harrower T, Young C, Lee M, Chhetri S, Ahmed F, Rog D, Silber E, Gallagher P, Duddy M, Straukiene A, Nicholas R, Rice C, Nixon SJ, Beveridge J, Hawton A, Tebbs S, Braisher M, Giovannoni G, Ciccarelli O, Greenwood J, Thompson AJ, Hunter R, Pavitt S, Pearson O, Evangelou N, Sharrack B, Galea I, Chandran S, Ford HL, Frost C, Chataway J. Blackstone J, et al. Among authors: arun t. BMJ Open. 2024 Sep 16;14(9):e086414. doi: 10.1136/bmjopen-2024-086414. BMJ Open. 2024. PMID: 39284697 Free PMC article. Clinical Trial.
89 results